Can a simple blood molecule predict blood vessel damage in kids with kidney disease?

NCT ID NCT06300788

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This study looks at whether levels of a molecule called inorganic pyrophosphate (PPi) in the blood are linked to blood vessel damage in children with chronic kidney disease (CKD). Researchers will compare PPi levels in children with CKD (including those on dialysis or with a kidney transplant) to levels in healthy children. The goal is to better understand why blood vessels harden in CKD and possibly find new ways to prevent it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If this study clarifies how pyrophosphate relates to blood vessel damage in children with kidney disease, it could point toward new ways to prevent or slow that damage.
What could go wrong: This is an observational study with a small number of participants (60 children). It measures molecules in the blood, so it cannot prove cause and effect or directly lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PYROPHOSPHATE, FETUIN A, IL1, IL6, TNFALPHA, CONTROL

Contacts and locations

Locations

CHU Nice - Hôpital de l'Archet 2
RECRUITING

Nice, Alpes-Maritimes, 06200, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.